UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
February 9, 2024
 
 
Date of Report (Date of earliest event reported)
 
     
 
NU SKIN ENTERPRISES, INC.
 
 
(Exact name of registrant as specified in its charter)
 

Delaware
 
001-12421
 
87-0565309
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification Number)


75 West Center Street
Provo, Utah 84601


(Address of principal executive offices and zip code)





(801) 345-1000


(Registrant’s telephone number, including area code)





N/A


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02
Results of Operations and Financial Condition.

On February 14, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 9, 2024, Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024. It is anticipated that he will transition to leading the Company’s Scientific Advisory Board. On February 10, 2024, the Company’s Board of Directors determined that the Chief Scientific Officer role is no longer an executive officer position. The Company and its management wish to express their appreciation to Dr. Chang for the important contributions he has made since joining the Company more than 20 years ago, and they look forward to his continued involvement with the Company.
 
Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Nu Skin Enterprises’ press release dated February 14, 2024, regarding financial results for the three-month and annual periods ended December 31, 2023.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

NU SKIN ENTERPRISES, INC.

(Registrant)

 

/s/ James D. Thomas
 

James D. Thomas

Chief Financial Officer

 
Date:  February 14, 2024
 




Exhibit 99.1


FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Fourth Quarter and Full-year 2023 Results
Above Company Guidance

Company updates capital allocation priorities, announces dividend
and provides initial outlook for Q1 and FY 2024

PROVO, Utah — Feb. 14, 2024 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2023 results slightly above its latest guidance.

Executive Summary
Q4 2023 vs. Prior-year Quarter

Revenue
   
$488.6 million; (6)%
   (1)% FX impact or $(7.2) million
•    Rhyz revenue $65.1 million; 101%
Earnings Per Share
(EPS)
   
$0.15 or $0.37 excluding restructuring and other charges, compared to $1.15 or $0.89 excluding restructuring and impairment charges and a favorable tax rate in Q4 22
Customers
   
977,039; (15)%
Paid Affiliates
   
166,886; (30)% or (13)% excluding an adjustment to eligibility requirements
Sales Leaders
   
44,059; (10)%

Executive Summary
2023 vs. 2022

Revenue:
   
$1.97 billion; (12)%
    (3)% FX impact or $(60.4) million
   Rhyz revenue $216.6 million; 41%
Earnings Per Share
(EPS):
   
$0.17 or $1.85 excluding inventory write-off and other charges, compared to $2.07 or $2.90 excluding restructuring and impairment charges
 

Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 2
“While we continue to work toward our long-term vision of becoming the world’s leading integrated beauty and wellness platform, our progress was impacted by persistent macro-economic pressures and disruptions associated with transforming our business,” said Ryan Napierski, Nu Skin president and CEO. “This was particularly evident with our fourth quarter results, which were down in our Americas, South Korea and Europe & Africa segments. This was offset by seasonal promotions in Mainland China, stabilization in Japan and modest growth in our Hong Kong/Taiwan segment. In addition, we achieved strong growth in our Rhyz businesses, which accounted for 13 percent of our revenue in the fourth quarter.
 
“We are committed to generating long-term enterprise value by repositioning our company to win in the rapidly evolving beauty and wellness industries by further transforming our core Nu Skin business and accelerating investment in our rapidly growing Rhyz ecosystem,” continued Napierski. “To enhance this transformation, we are reassessing our approach to capital allocation to invest in long-term growth and business evolution. This initiative aims to grant us increased financial flexibility, enabling us to effectively seize forthcoming growth opportunities. This includes rebalancing our dividend payout ratio to be in line with or better than our industry peers. With the additional available capital, we will focus our investments relatively evenly across three key initiatives: 1) accelerating the growth opportunities in Rhyz; 2) facilitating a new market expansion model beginning with India anticipated in 2025; and 3) furthering the build-out of our digital-first affiliate opportunity platform. While we continue to navigate the challenges of a business transformation amid these disruptive times, we have fine-tuned our strategy and remain confident in our ability to generate long-term growth and value for shareholders.”

Q4 2023 Year-over-year Operating Results

Revenue
   
$488.6 million compared to $522.3 million
    (1)% FX impact or $(7.2) million
    Rhyz revenue $65.1 million; 101%
Gross Margin
   
72.1% compared to 71.7%
          Nu Skin business was 77.4% compared to 74.9%
Selling Expenses
   
37.1% compared to 38.5%
    Nu Skin business was 40.8% compared to 40.5%
G&A Expenses
   
29.7% compared to 24.4%
Operating Margin
   
3.3% or 6.4% excluding restructuring and other charges compared to 5.3% or 8.8% excluding restructuring and impairment charges
Other Expense
   
$(6.7) million compared to $(3.1) million
Income Tax Rate
   
21.9% or 24.9% excluding restructuring and other charges compared to (134.9)% or (3.7)% excluding restructuring and impairment charges
EPS
   
$0.15 or $0.37 excluding restructuring and other charges compared to $1.15 or $0.89 excluding restructuring and impairment charges and a tax method change


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 3
Stockholder Value

Dividend Payments
   
$19.3 million
Stock Repurchases
   
$0.0 million
    $162.4 million remaining in authorization

Q1 and Full-year 2024 Outlook

Q1 2024 Revenue
   
$400 to $435 million; (17)% to (10)%
    Approximately (3) to (2)% FX impact
Q1 2024 EPS
   
$(0.07) to $0.03 or $0.00 to $0.10 non-GAAP
2024 Revenue
   
$1.73 to $1.87 billion; (12)% to (5)%
    Approximately (1)% FX impact
2024 EPS
   
$0.75 to $1.15 or $0.95 to $1.35 non-GAAP

“Our initial 2024 guidance assumes the global macro environment remains challenging in the near-term, improving throughout the year,” said James D. Thomas, chief financial officer. “Our annual revenue guidance is $1.73 to $1.87 billion, with an approximate 1% foreign currency headwind. We anticipate reported EPS of $0.75 to $1.15 or adjusted earnings of $0.95 to $1.35, excluding charges associated with our extended restructuring plan. Our guidance reflects an anticipated higher global effective tax rate, primarily due to the expected geographical mix of earnings during the year. For the first quarter, we project revenue of $400 to $435 million, assuming a negative foreign currency impact of approximately 3%, with reported earnings per share of $(0.07) to $0.03 or $0.00 to $0.10 excluding restructuring charges.”
 
Dividend Payout
The Nu Skin Enterprises board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 6, 2024, to shareholders of record on Feb. 26, 2024.
 

Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 4
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through Feb. 28, 2024.
 
About Nu Skin Enterprises Inc.
The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by nearly 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro environment and the company’s performance, growth and growth opportunities, shareholder value, financial flexibility, transformation, evolution, investments, initiatives, digital tools and initiatives, and new market expansion; projections regarding revenue, expenses, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “aim,” “commit,” “reposition”, “anticipate,” “accelerate,” “project,” “vision,” “continue,” “outlook,” “guidance,” “improve,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:


any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

economic conditions and events globally;


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 5

competitive pressures in the company’s markets;

risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;

adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

uncertainties regarding the future financial performance of the businesses the company has acquired;

risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and

the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
 
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin and income tax rate, each excluding inventory write-off charges, restructuring charges, and/or other charges, also are non-GAAP financial measures. Inventory write-off charges and restructuring charges are not part of the ongoing operations of our underlying business, and the legal accrual and non-recurring foreign tax charge that have been excluded in the non-GAAP financial measures are not typical for our ongoing operations. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 6
The following table sets forth revenue for the three-month periods ended December 31, 2023, and 2022 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
December 31,
   
Change
     
Constant-
Currency
Change
  
   
2023
   
2022
   
Nu Skin
                       
Americas
 
$
97,753
   
$
128,921
     
(24
)%
   
(19
)%
Mainland China
   
71,516
     
73,935
     
(3
)%
   
(2
)%
Southeast Asia/Pacific
   
66,889
     
76,606
     
(13
)%
   
(12
)%
South Korea
   
48,380
     
60,029
     
(19
)%
   
(22
)%
Japan
   
50,966
     
53,877
     
(5
)%
   
(1
)%
Europe & Africa
   
47,892
     
55,337
     
(13
)%
   
(18
)%
Hong Kong/Taiwan
   
41,209
     
39,789
     
4
%
   
5
%
Nu Skin other
   
(1,066
)
   
1,525
     
(170
)%
   
(170
)%
Total Nu Skin
   
423,539
     
490,019
     
(14
)%
   
(12
)%
Rhyz
                               
Manufacturing
   
50,363
     
29,560
     
70
%
   
70
%
Rhyz other
   
14,738
     
2,761
     
434
%
   
434
%
Total Rhyz
   
65,101
     
32,321
     
101
%
   
101
%
Total
 
$
488,640
   
$
522,340
     
(6
)%
   
(5
)%

The following table sets forth revenue for the years ended December 31, 2023, and 2022 for each of our reportable segments (U.S. dollars in thousands):

   
Year Ended
December 31,
   
Change
     
Constant-
Currency
Change
  
   
2023
   
2022
   
Nu Skin
                       
Americas
 
$
398,222
   
$
508,537
     
(22
)%
   
(18
)%
Mainland China
   
298,079
     
360,389
     
(17
)%
   
(13
)%
Southeast Asia/Pacific
   
267,206
     
344,411
     
(22
)%
   
(21
)%
South Korea
   
236,099
     
268,707
     
(12
)%
   
(11
)%
Japan
   
207,833
     
224,896
     
(8
)%
   
(1
)%
Europe & Africa
   
192,352
     
204,275
     
(6
)%
   
(8
)%
Hong Kong/Taiwan
   
153,589
     
157,197
     
(2
)%
   
1
%
Nu Skin other
   
-858
     
3,959
     
(122
)%
   
(122
)%
Total Nu Skin
   
1,752,522
     
2,072,371
     
(15
)%
   
(13
)%
Rhyz
                               
Manufacturing
   
181,395
     
149,458
     
21
%
   
21
%
Rhyz other
   
35,214
     
3,830
     
819
%
   
819
%
Total Rhyz
   
216,609
     
153,288
     
41
%
   
41
%
Total
 
$
1,969,131
   
$
2,225,659
     
(12
)%
   
(9
)%


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 7
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended December 31, 2023, and 2022:

   
Year Ended
December 31,
   
Change
 
   
2023
   
2022
     
Customers
                 
Americas
   
231,183
     
299,287
     
(23
)%
Mainland China
   
207,276
     
202,933
     
2
%
Southeast Asia/Pacific
   
106,471
     
141,183
     
(25
)%
South Korea
   
103,151
     
123,749
     
(17
)%
Japan
   
113,670
     
119,152
     
(5
)%
Europe & Africa
   
163,178
     
197,917
     
(18
)%
Hong Kong/Taiwan
   
52,110
     
62,903
     
(17
)%
Total Customers
   
977,039
     
1,147,124
     
(15
)%

Paid Affiliates
                 
Americas
   
31,910
     
42,633
     
(25
)%
Mainland China
   
25,889
     
23,436
     
10
%
Southeast Asia/Pacific
   
34,404
     
38,653
     
(11
)%
South Korea(1)
   
22,166
     
45,058
     
(51
)%
Japan(1)
   
22,417
     
38,021
     
(41
)%
Europe & Africa(1)
   
18,888
     
31,869
     
(41
)%
Hong Kong/Taiwan(1)
   
11,212
     
17,286
     
(35
)%
Total Paid Affiliates
   
166,886
     
236,956
     
(30
)%

Sales Leaders
                 
Americas
   
7,126
     
9,594
     
(26
)%
Mainland China
   
11,296
     
12,359
     
(9
)%
Southeast Asia/Pacific
   
6,418
     
6,999
     
(8
)%
South Korea
   
5,249
     
6,094
     
(14
)%
Japan
   
7,086
     
5,936
     
19
%
Europe & Africa
   
3,968
     
4,740
     
(16
)%
Hong Kong/Taiwan
   
2,916
     
3,015
     
(3
)%
Total Sales Leaders
   
44,059
     
48,737
     
(10
)%

(1)  The December 31, 2023, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters. We estimate the change in eligibility requirements resulted in a reduction of approximately 14 thousand, 15 thousand, 6 thousand and 3 thousand for South Korea, Japan, Europe & Africa and Hong Kong/Taiwan, respectively.


“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.


“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.


“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
December 31,
   
Year Ended
December 31,
 
   
2023
   
2022
   
2023
   
2022
 
Revenue
 
$
488,640
   
$
522,340
   
$
1,969,131
   
$
2,225,659
 
Cost of sales
   
136,215
     
147,816
     
611,850
     
630,915
 
Gross profit
   
352,425
     
374,524
     
1,357,281
     
1,594,744
 
                                 
Operating expenses:
                               
Selling expenses
   
181,326
     
201,031
     
742,365
     
879,634
 
General and administrative expenses
   
145,033
     
127,664
     
546,858
     
555,769
 
Restructuring and impairment expenses
   
10,003
     
18,370
     
19,790
     
48,494
 
Total operating expenses
   
336,362
     
347,065
     
1,309,013
     
1,483,897
 
                                 
Operating income (loss)
   
16,063
     
27,459
     
48,268
     
110,847
 
Other income (expense), net
   
(6,735
)
   
(3,104
)
   
(21,690
)
   
(21,877
)
                                 
Income (loss) before provision for income taxes
   
9,328
     
24,355
     
26,578
     
88,970
 
Provision (benefit) for income taxes
   
2,046
     
(32,860
)
   
17,983
     
(15,808
)
                                 
Net income (loss)
 
$
7,282
   
$
57,215
   
$
8,595
   
$
104,778
 
                                 
Net income (loss) per share:
                               
Basic
 
$
0.15
   
$
1.16
   
$
0.17
   
$
2.10  
Diluted
 
$
0.15
   
$
1.15
   
$
0.17
   
$
2.07
 
                                 
Weighted-average common shares outstanding (000s):
                               
Basic
   
49,411
     
49,452
     
49,711
     
50,002
 
Diluted
   
49,479
     
49,783
     
49,860
     
50,525
 


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
December 31,
2023
   
December 31,
2022
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
256,057
   
$
264,725
 
Current investments
   
11,759
     
13,784
 
Accounts receivable, net
   
72,879
     
47,360
 
Inventories, net
   
279,978
     
346,183
 
Prepaid expenses and other
   
81,198
     
87,816
 
Total current assets
   
701,871
     
759,868
 
                 
Property and equipment, net
   
432,965
     
444,806
 
Operating lease right-of-use assets
   
90,107
     
98,734
 
Goodwill
   
230,768
     
206,432
 
Other intangible assets, net
   
105,309
     
66,701
 
Other assets
   
245,443
     
244,429
 
Total assets
 
$
1,806,463
   
$
1,820,970
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
 
$
43,505
   
$
53,963
 
Accrued expenses
   
260,366
     
280,280
 
Current portion of long-term debt
   
25,000
     
25,000
 
Total current liabilities
   
328,871
     
359,243
 
                 
Operating lease liabilities
   
70,943
     
76,540
 
Long-term debt
   
478,040
     
377,466
 
Other liabilities
   
106,641
     
110,425
 
Total liabilities
   
984,495
     
923,674
 
                 
Commitments and contingencies
               
                 
Stockholders’ equity:
               
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
   
91
     
91
 
Additional paid-in capital
   
621,853
     
613,278
 
Treasury stock, at cost – 41.1 million and 41.1 million shares
   
(1,570,440
)
   
(1,569,061
)
Accumulated other comprehensive loss
   
(100,006
)
   
(86,509
)
Retained earnings
   
1,870,470
     
1,939,497
 
Total stockholders’ equity
   
821,968
     
897,296
 
Total liabilities and stockholders’ equity
 
$
1,806,463
   
$
$1,820,970
 


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 10
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Impact of Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)

   
Three months ended
December 31,
   
Year ended
December 31,
 
   
2023
   
2022
   
2023
   
2022
 
Operating Income
 
$
16,063
   
$
27,459
   
$
48,268
   
$
110,847
 
Impact of inventory write-off
   
-
     
-
     
65,728
     
26,905
 
Impact of restructuring and impairment
   
10,003
     
18,370
     
19,790
     
48,494
 
Impact of other charges(2)
   
5,260
     
-
     
5,260
     
-
 
Adjusted operating income
 
$
31,326
   
$
45,829
   
$
139,046
   
$
186,246
 
                                 
                                 
Operating margin
   
3.3
%
   
5.3
%
   
2.5
%
   
5.0
%
Operating margin, excluding impact of certain charges
   
6.4
%
   
8.8
%
   
7.1
%
   
8.4
%
                                 
Revenue
 
$
488,640
   
$
522,340
   
$
1,969,131
   
$
2,225,659
 


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 11
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)

   
Three months ended
December 31,
   
Year ended
December 31,
 
   
2023
   
2022
   
2023
   
2022
 
Provision (benefit) for income taxes
 
$
2,046
   
$
(32,860
)
 
$
17,983
   
$
(15,808
)
Impact of certain charges on provision for income taxes
   
4,081
     
31,284
     
7,324
     
42,838
 
Provision for income taxes, excluding impact of certain charges
 
$
6,127
   
$
(1,576
)
 
$
25,307
   
$
27,030
 
                                 
Income before provision for income taxes
   
9,328
     
24,355
     
26,578
     
88,970
 
Impact of inventory write-off
   
-
     
-
     
65,728
     
26,905
 
Impact of restructuring and impairment
   
10,003
     
18,370
     
19,790
     
48,494
 
Impact of other charges(2)
   
5,260
     
-
     
5,260
     
-
 
Impact of charges associated with our exit from Grow Tech:
                               
Unrealized investment loss
   
-
     
-
     
-
     
9,009
 
Income before provision for income taxes, excluding impact of certain charges
 
$
24,591
   
$
42,725
   
$
117,356
   
$
173,378
 
                                 
Effective tax rate
   
21.9
%
   
(134.9
)%
   
67.7
%
   
(17.8
)%
Effective tax rate, excluding impact of certain charges
   
24.9
%
   
(3.7
)%
   
21.6
%
   
15.6
%


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 12
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)

   
Three months ended
December 31,
   
Year ended
December 31,
 
   
2023
   
2022
   
2023
   
2022
 
Net income
 
$
7,282
   
$
57,215
   
$
8,595
   
$
104,778
 
Impact of restructuring and inventory write-off expense:
                               
Restructuring and impairment
   
10,003
     
18,370
     
19,790
     
48,494
 
Inventory write-off
   
-
     
-
     
65,728
     
26,905
 
Tax impact
   
(3,088
)
   
903
     
(6,331
)
   
(9,566
)
Impact of other charges: (2)
                               
Impact of other charges
   
5,260
             
5,260
         
Tax impact
   
(993
)
   
-
     
(993
)
   
-
 
Impact of charges associated with our exit from Grow Tech:
                               
Unrealized loss on investment
   
-
     
-
     
-
     
9,009
 
Tax impact
   
-
     
-
     
-
     
(1,085
)
Tax impact
   
-
     
(32,187
)
   
-
     
(32,187
)
Adjusted net income
 
$
18,464
   
$
44,301
   
$
92,049
   
$
146,348
 
                                 
Diluted earnings per share
 
$
0.15
   
$
1.15
   
$
0.17
   
$
2.07
 
Diluted earnings per share, excluding impact of certain charges
 
$
0.37
   
$
0.89
   
$
1.85
   
$
2.90
 
                                 
Weighted-average common shares outstanding (000)
   
49,479
     
49,783
     
49,860
     
50,525
 

(2)  Other charges consist of a legal contingency ($3.0 million) and a non-recurring foreign tax charge ($2.3 million) that were recorded in the fourth quarter of 2023.


Nu Skin Enterprises Reports Fourth Quarter and 2023 Financial Results
page 13
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

   
Three months ended
March 31,
   
Year ended
December 31,
 
   
2024 - Low-
end
   
2024 High-
end
   
2024 - Low-
end
   
2024 High-
end
 
Earnings Per Share
 
$
(0.07
)
 
$
0.03
   
$
0.75
   
$
1.15
 
Impact of restructuring expense:
                               
Restructuring
   
0.10
     
0.10
     
0.30
     
0.30
 
Tax impact
   
(0.03
)
   
(0.03
)
   
(0.10
)
   
(0.10
)
Adjusted EPS
 
$
-
   
$
0.10
   
$
0.95
   
$
1.35
 

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577